NCT02293967View on ClinicalTrials.gov

Mass Balance Study of MT-1303

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

MT-1303

Trial Locations (1)

Unknown

Investigational site, Ruddington

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY